Jumping on the bandwagon about escalating drug prices, the U.S. hospital industry released a report Tuesday showing how random, unpredictable drug costs are hurting community hospitals.
The biggest culprit isn't new specialty drugs with six-figure price tags. Rather, it's the stable of older go-to drugs, several of which have no market competition even though they are high volume and their patents died out years ago.
The report, compiled by NORC at the University of Chicago for the American Hospital Association and the Federation of American Hospitals, noted that some drug companies, such as Valeant Pharmaceuticals International Inc., of Laval, Quebec, specifically directed their price increases to hospital-administered drugs.
According to a staff memo to the Democrats serving on the House